| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Oncology, Markers, Clinical Correlates |
1 The Robert H. Lurie Comprehensive Cancer Center and 2 Department of Pediatrics, Northwestern University, Feinberg School of Medicine, Chicago, Illinois
Purpose: To investigate the prevalence and potential clinical significance of epigenetic aberrations in neuroblastoma (NB).
Experimental Design: The methylation status of 11 genes that are frequently epigenetically inactivated in adult cancers was assayed in 13 NB cell lines. The prevalence of RASSF1A and TSP-1 methylation was also analyzed in 56 NBs and 5 ganglioneuromas by methylation-specific PCR. Associations between the methylation status of RASSF1A and TSP-1 and patient age, tumor stage, tumor MYCN status, and patient survival were evaluated.
Results: Epigenetic changes were detected in all 13 NB cell lines, although the pattern of gene methylation varied. The putative tumor suppressor gene RASSF1A was methylated in all 13 cell lines, and TSP-1 and CASP8 were methylated in 11 of 13 cell lines. Epigenetic changes of DAPK and FAS were detected in only small numbers of cell lines, whereas none of the cell lines had methylation of p16, p21, p73, RAR-ß2, SPARC, or TIMP-3. RASSF1A was also methylated in 70% of the primary NB tumors tested, and TSP-1 methylation was detected in 55% of the tumors. RASSF1A methylation was significantly associated with age >1 year (P < 0.01), high-risk disease (P < 0.016), and poor survival (P < 0.001). In contrast, no association between TSP-1 methylation and prognostic factors or survival was observed.
Conclusions: Our results suggest that epigenetic inactivation of RASSF1A may contribute to the clinically aggressive phenotype of high-risk NB.
This article has been cited by other articles:
|
|
 |
|
  Q. Yang, C. M. Kiernan, Y. Tian, H. R. Salwen, A. Chlenski, B. A. Brumback, W. B. London, and S. L. Cohn Methylation of CASP8, DCR2, and HIN-1 in Neuroblastoma Is Associated with Poor Outcome Clin. Cancer Res., June 1, 2007; 13(11): 3191 - 3197. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Wang, S. Diskin, E. Rappaport, E. Attiyeh, Y. Mosse, D. Shue, E. Seiser, J. Jagannathan, S. Shusterman, M. Bansal, et al. Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. Cancer Res., June 15, 2006; 66(12): 6050 - 6062. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. H. Wei, C. Balch, H. H. Paik, Y.-S. Kim, R. L. Baldwin, S. Liyanarachchi, L. Li, Z. Wang, J. C. Wan, R. V. Davuluri, et al. Prognostic DNA methylation biomarkers in ovarian cancer. Clin. Cancer Res., May 1, 2006; 12(9): 2788 - 2794. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. van der Weyden, K. K. Tachibana, M. A. Gonzalez, D. J. Adams, B. L. Ng, R. Petty, A. R. Venkitaraman, M. J. Arends, and A. Bradley The RASSF1A Isoform of RASSF1 Promotes Microtubule Stability and Suppresses Tumorigenesis Mol. Cell. Biol., September 15, 2005; 25(18): 8356 - 8367. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Dallol, A. Agathanggelou, S. Tommasi, G. P. Pfeifer, E. R. Maher, and F. Latif Involvement of the RASSF1A Tumor Suppressor Gene in Controlling Cell Migration Cancer Res., September 1, 2005; 65(17): 7653 - 7659. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
